CN113200979A - Synthesis process of solifenacin succinate - Google Patents
Synthesis process of solifenacin succinate Download PDFInfo
- Publication number
- CN113200979A CN113200979A CN202110393406.0A CN202110393406A CN113200979A CN 113200979 A CN113200979 A CN 113200979A CN 202110393406 A CN202110393406 A CN 202110393406A CN 113200979 A CN113200979 A CN 113200979A
- Authority
- CN
- China
- Prior art keywords
- solifenacin
- reaction
- solifenacin succinate
- solvent
- synthesizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FBOUYBDGKBSUES-KEKNWZKVSA-N 1-azabicyclo[2.2.2]octan-3-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(OC2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-KEKNWZKVSA-N 0.000 title claims abstract description 40
- 229960001368 solifenacin succinate Drugs 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 30
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 14
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 62
- 229960003855 solifenacin Drugs 0.000 claims abstract description 35
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims abstract description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims abstract description 18
- PRTRSEDVLBBFJZ-HNNXBMFYSA-N (1s)-1-phenyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1([C@H]2C3=CC=CC=C3CCN2)=CC=CC=C1 PRTRSEDVLBBFJZ-HNNXBMFYSA-N 0.000 claims abstract description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- IVLICPVPXWEGCA-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@H](O)CN1CC2 IVLICPVPXWEGCA-ZETCQYMHSA-N 0.000 claims description 15
- 239000005457 ice water Substances 0.000 claims description 12
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 230000002194 synthesizing effect Effects 0.000 claims description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 9
- 239000007810 chemical reaction solvent Substances 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- WGNZRZSJIVMRBU-ZETCQYMHSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] carbonochloridate Chemical compound C1CC2[C@@H](OC(=O)Cl)CN1CC2 WGNZRZSJIVMRBU-ZETCQYMHSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000012043 crude product Substances 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000012074 organic phase Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 2
- 238000009833 condensation Methods 0.000 abstract description 5
- 230000005494 condensation Effects 0.000 abstract description 5
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 5
- 230000000269 nucleophilic effect Effects 0.000 abstract description 4
- 230000002441 reversible effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000013067 intermediate product Substances 0.000 abstract description 3
- 125000004185 ester group Chemical group 0.000 abstract 1
- 239000002585 base Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical group 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- AJFJHHJTKIFNBK-RSAXXLAASA-N carbamoyl chloride (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C(N)(=O)Cl.C1(=CC=CC=C1)[C@@H]1NCCC2=CC=CC=C12 AJFJHHJTKIFNBK-RSAXXLAASA-N 0.000 description 4
- 238000005809 transesterification reaction Methods 0.000 description 4
- -1 chloroformic acid- (R) -3-quinuclidinol ester Chemical class 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000029436 dilated pupil Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
Abstract
A synthesis process of solifenacin succinate relates to the technical field of medicines. It comprises the following steps: firstly, generating chloroformic acid- (R) -3-quinuclidine ester (C) by (R) -3-quinuclidine alcohol (B) and a reaction substance; step two, reacting (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline (A) with chloromethyl- (R) -3-quinuclidine ester (C) to generate solifenacin (D); and step three, preparing the solifenacin (D) into the solifenacin succinate. After the technical scheme is adopted, the invention has the beneficial effects that: the synthesis process not only avoids the problem of low conversion rate caused by direct ester exchange reaction, but also reduces the probability of occurrence of reversible reaction caused by nucleophilic intermediate product generated in the condensation process, and greatly promotes the reaction, thereby improving the yield of solifenacin succinate, and the synthesis process has mild reaction conditions, simple operation, reduced operation procedures and suitability for large-scale production.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a synthesis process of solifenacin succinate.
Background
Solifenacin succinate, chemically (3R) -1-azabicyclo [2.2.2] oct-3-yl (1S) -1-phenyl-3, 4-dihydroisoquinoline-2- (1H) -carboxylate succinate, is a selective muscarinic M3 receptor antagonist developed by Astelas, Japan. The product can selectively relax bladder detrusor, and reduce systemic adverse reaction of conventional anticholinergic drugs, such as xerostomia, constipation, dilated pupil, tachycardia, etc.
EP0801067 (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline is condensed with ethyl chloroformate, and then ester exchange reaction is carried out on the condensed product and (R) -3-quinuclidinol under the catalysis of sodium hydride as base to synthesize solifenacin; the reaction was carried out under reflux in toluene and the ethanol produced was distilled azeotropically. W02008/077357 is also synthesized by condensing (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline with ethyl chloroformate and then carrying out exchange reaction with (R) -3-quinuclidine alcohol ester to obtain solifenacin, which is only catalyzed by potassium tert-butoxide and is also catalyzed by refluxing and azeotroping toluene to carry away ethanol. US2009/0099365 also reports transesterification with NaH as base and DMF as solvent, and the conversion was not improved. The transesterification reaction has low conversion rate related to the byproduct ethanol generated by condensation; ethanol can form sodium ethoxide under the action of strong yelling action, such as the presence of sodium hydride, and also has strong nucleophilic ability, so that the product returns to the initial raw material.
CN102875544, wherein carbamoyl is chlorinated with (S) -1-phenyl-1, 2,3, 4-tetraradon isoquinoline, the (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline carbamoyl chloride is reacted with (R) -3-quinuclidinol metal salt to produce solifenacin base, and the solifenacin base is then synthesized into solifenacin succinate, which avoids the problem of low conversion rate of transesterification reaction, but the operation for preparing solifenacin base is complicated and the prepared (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline carbamoyl chloride is unstable.
Disclosure of Invention
The invention aims to provide a synthesis process of solifenacin succinate aiming at the defects and shortcomings of the prior art, so that the problem of low conversion rate of ester exchange reaction is avoided, the operation is simplified, the yield of solifenacin succinate is improved, and the synthesis process can be better applied to industrial production.
In order to achieve the purpose, the invention adopts the following technical scheme: it comprises the following steps:
firstly, generating chloroformic acid- (R) -3-quinuclidine ester (C) by (R) -3-quinuclidine alcohol (B) and a reaction substance;
step two, reacting (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline (A) with chloromethyl- (R) -3-quinuclidine ester (C) to generate solifenacin (D);
and step three, preparing the solifenacin (D) into the solifenacin succinate.
Adding (R) -3-quinuclidinol (B) into a solvent, after the (R) -3-quinuclidinol (B) is dissolved, dropwise adding a reaction substance into the system in an ice-water bath, scattering the system in the ice-water bath after the dropwise adding is finished, reacting at room temperature for 16h, and concentrating to obtain the (R) -3-quinuclidinol chloroformate (C).
And in the second step, (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline (A) and an acid-binding agent are added into a reaction solvent, a chloroformic acid- (R) -3-quinuclidine ester (C) solution which is dissolved and diluted by the reaction solvent is dropwise added in an ice bath, stirring is carried out for 3-10 min after the addition is finished, an ice water bath is removed, stirring reaction is continued, a crude product of the solifenacin (D) is obtained by concentration, the crude product of the solifenacin (D) is dissolved by a post-treatment solvent, an organic phase is washed, and the solifenacin (D) is obtained by concentration.
The preparation method of solifenacin succinate in the third step comprises the specific steps of adding solifenacin (D) into ethyl acetate, adding absolute ethyl alcohol and succinic acid, heating to reflux, naturally cooling for crystallization after reflux reaction, filtering and drying to obtain the solifenacin succinate.
The reaction substance in the first step is one of phosgene, diphosgene and triphosgene; the reactant of the present invention is preferably diphosgene.
In the first step, the solvent is one of acetonitrile, tetrahydrofuran and dioxane; acetonitrile is preferred as the solvent of the present invention.
In the second step, the acid-binding agent is one of morpholine, N-methylmorpholine, triethylamine, pyridine or 4-methylpyridine; triethylamine is preferred as the acid-binding agent of the invention.
In the second step, the reaction solvent is one of tetrahydrofuran, dichloromethane and dioxane; the solvent for the reaction of the present invention is preferably dichloromethane.
The post-treatment solvent in the second step is one of ethyl acetate, dichloromethane and methyl tert-butyl ether; the working-up solvent according to the invention is preferably dichloromethane.
The working principle of the invention is as follows: firstly, reacting (R) -3-quinuclidinol (B) with a reaction substance to generate chloroformic acid- (R) -3-quinuclidinyl ester (C); then (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline (A) reacts with chloromethyl- (R) -3-quinuclidine ester (C) to generate solifenacin (D), and the solifenacin (D) is prepared into solifenacin succinate; the names and the reaction processes of various substances participating in the reaction are described, including a reaction solvent, a solution dropping sequence and the like, but the dosage of various substances and solvents is not limited; theoretically, as long as the above-mentioned various substances are not 0, the reaction can proceed and the target product solifenacin succinate can be produced; the dosage of each substance can be better limited according to the proportion of the amount of each substance in the chemical formula of the reaction and the conventional design in the chemical reaction; even if the specific ratio of each substance is not given, the method can still be better implemented.
After the technical scheme is adopted, the invention has the beneficial effects that: the synthesis process not only avoids low conversion rate caused by direct ester exchange reaction, but also reduces the probability of occurrence of reversible reaction caused by nucleophilic intermediate product generated in the condensation process, greatly promotes the reaction, thereby improving the yield of solifenacin succinate, has mild reaction conditions and simple operation, reduces operation procedures, and is suitable for large-scale production.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
FIG. 1 is a schematic diagram of the structure of solifenacin succinate of the present invention;
FIG. 2 is a schematic diagram of the transesterification synthesis route in prior art EP 0801067;
FIG. 3 is a schematic diagram of the synthetic route in prior art CN 102875544;
FIG. 4 is a schematic representation of the reaction scheme of example 1 of the present invention;
FIG. 5 is a schematic representation of the reaction scheme of example 2 of the present invention.
Detailed Description
Example 1
Referring to fig. 4, the technical solution adopted by the present embodiment is:
1. firstly, 10.0g of (R) -3-quinuclidinol is added into 800.0ml of acetonitrile, after the acetonitrile is dissolved, 20.0g of diphosgene is dropwise added into the system in an ice water bath, after the dropwise addition is finished, the ice water bath is scattered, the reaction is carried out for 16h at the room temperature, and 13.4g of chloroformic acid- (R) -3-quinuclidinol ester is obtained by concentration.
2. Adding 11.3g of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline and 8.2g of triethylamine into 100.0ml of dichloromethane, dropwise adding 13.4g of chloroformic acid- (R) -3-quinuclidine ester solution diluted by 60.0ml of dichloromethane in an ice bath, stirring for 3-10 min after the addition is finished, removing the ice water bath, continuing stirring for reaction, concentrating to obtain a crude product of solifenacin, dissolving with 100.0ml of dichloromethane, washing an organic phase with water, and concentrating to obtain 17.6g of solifenacin.
3. Adding 17.6g of solifenacin oily matter into 20.0mL of ethyl acetate, adding 10.0mL of absolute ethyl alcohol and 5.8g of succinic acid, heating to reflux, refluxing for 1h, naturally cooling for crystallization, filtering, and drying to obtain 16.4g of solifenacin succinate, wherein the total yield is 63.0% in terms of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline, and the purity HPLC: 99 percent.
Example 2
Referring to fig. 5, the technical solution adopted by the present embodiment is:
1. adding 10.0g of (R) -3-quinuclidinol into 600.0ml of THF, after the solution is dissolved, dropwise adding 20.0g of diphosgene into the system in an ice water bath, scattering the system in the ice water bath after the dropwise addition is finished, reacting at room temperature for 16h, and concentrating to obtain 13.8g of chloroformic acid- (R) -3-quinuclidinol ester.
2. Adding 11.3g of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline and 6.4g of pyridine into 100.0ml of dichloromethane, dropwise adding 13.8g of chloroformic acid- (R) -3-quinuclidine ester solution diluted by 62.0ml of dichloromethane in an ice bath, stirring for 3-10 min after the addition is finished, removing the ice water bath, continuing stirring for reaction, concentrating to obtain a crude product of solifenacin, dissolving the crude product by using 100.0ml of dichloromethane, washing an organic phase by water, and concentrating to obtain 18.0g of solifenacin.
3. Adding 18.0g of solifenacin oily matter into 23.0mL of ethyl acetate, adding 18.0mL of absolute ethyl alcohol and 9.2g of succinic acid, heating to reflux, refluxing for 1h, naturally cooling for crystallization, filtering and drying to obtain 16.7g of solifenacin succinate, wherein the total yield is 61% and the purity is more than 99% according to HPLC (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline).
In examples 1 and 2, the amounts and parameters (such as reaction time and stirring time) of each reaction substance and solvent are only the preferable amounts and parameters in this example, but the specific values are not intended to limit the present invention, theoretically, the reaction can proceed and the desired product solifenacin succinate can be produced as long as the above-mentioned substances are not 0; in the scheme of the invention, different condensation solvents are used, different acid-binding agents are used, the dosage and parameter values can be adjusted within a certain range according to the change of production environment and other factors, and the dosage of each substance can be better limited according to the conventional design in chemical reaction.
Example 3
Referring to fig. 4, the difference from embodiment 1 is: the experiment was carried out with replacement of the reaction solvent therein, each time with a change of one of the solvent components.
1 adding (R) -3-quinuclidinol into a solvent and reacting the mixture with diphosgene to obtain chloroformic acid- (R) -3-quinuclidinyl ester, wherein acetonitrile, tetrahydrofuran, dioxane and dichloromethane are adopted as reaction solvents for generating the chloroformic acid- (R) -3-quinuclidinyl ester, and the obtained chloroformic acid- (R) -3-quinuclidinyl ester has the total yield of solifenacin succinate which is acetonitrile (63%), tetrahydrofuran (61%), dioxane (47%) and dichloromethane (29%).
Dissolving 2 (R) -3-quinuclidinol in acetonitrile, and reacting with phosgene, diphosgene or triphosgene respectively to generate chloroformic acid- (R) -3-quinuclidinol ester, wherein the total yield of the prepared solifenacin succinate is about 60 percent.
3 synthesizing solifenacin by using (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline and chloroformic acid- (R) -3-quinuclidine ester, wherein morpholine, N-methylmorpholine, triethylamine, pyridine and 4-methylpyridine are used as bases, and tetrahydrofuran is used as a solvent; the total yield of the finally prepared solifenacin succinate is about 60 percent
According to the screening of the components, the combination of different components has certain influence on the yield of the synthesized solifenacin succinate, the (R) -3-quinuclidinol is dissolved in acetonitrile through the comparison of the results of the experimental components, and then the chloroformic acid- (R) -3-quinuclidinyl ester is synthesized by diphosgene; synthesizing solifenacin by using (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline and (R) -3-quinuclidinol, and using triethylamine as base, reacting and post-treating solvent and dichloromethane; finally, solifenacin is salified with succinic acid. The reaction can be promoted to the maximum extent by matching the components, so that the yield of solifenacin succinate is improved, and the method is suitable for large-scale production; as described above, the present invention can be preferably carried out.
In the existing preparation and synthesis process of solifenacin succinate, the (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline is condensed with ethyl chloroformate and then subjected to ester exchange with (R) -3-quinuclidinol under the catalysis of strong base to obtain the solifenacin, and alkali and ethanol are reacted to form sodium alcoholate, so that the reaction is carried out reversely, and the conversion rate is reduced. While the reaction of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline carbamoyl chloride with (R) -3-quinuclidinol metal salt to give solifenacin base, the preparation of solifenacin base is complicated and (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline carbamoyl chloride is unstable. The operation is simplified in order to increase the conversion and increase the reaction yield. In the technical scheme provided by the invention, chloroformic acid- (R) -3-quinuclidine ester (C) is generated by (R) -3-quinuclidine alcohol (B) and diphosgene, the reaction is simple to operate, then (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline (A) and chloro-methyl- (R) -3-quinuclidine ester (C) are subjected to condensation reaction to generate solifenacin (D), the reaction conversion rate is high, and the solifenacin (D) is prepared into solifenacin succinate, so that the occurrence of reverse reaction in ester exchange reaction is avoided, the reaction is promoted, the conversion rate is improved, the reaction process is mild, the operation is simplified, and the method is suitable for large-scale production.
After the technical scheme is adopted, the invention has the beneficial effects that: the synthesis process not only avoids the problem of low conversion rate caused by direct ester exchange reaction, but also reduces the probability of occurrence of reversible reaction caused by nucleophilic intermediate product generated in the condensation process, and greatly promotes the reaction, thereby improving the yield of solifenacin succinate, and the synthesis process has mild reaction conditions, simple operation, reduced operation procedures and suitability for large-scale production.
The above description is only for the purpose of illustrating the technical solutions of the present invention and not for the purpose of limiting the same, and other modifications or equivalent substitutions made by those skilled in the art to the technical solutions of the present invention should be covered within the scope of the claims of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (9)
1. A synthesis process of solifenacin succinate is characterized by comprising the following steps: it comprises the following steps:
firstly, generating chloroformic acid- (R) -3-quinuclidine ester (C) by (R) -3-quinuclidine alcohol (B) and a reaction substance;
step two, reacting (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline (A) with chloromethyl- (R) -3-quinuclidine ester (C) to generate solifenacin (D);
and step three, preparing the solifenacin (D) into the solifenacin succinate.
2. The process for synthesizing solifenacin succinate as claimed in claim 1, wherein: adding (R) -3-quinuclidinol (B) into a solvent, after the (R) -3-quinuclidinol (B) is dissolved, dropwise adding a reaction substance into the system in an ice-water bath, scattering the system in the ice-water bath after the dropwise adding is finished, reacting at room temperature for 16h, and concentrating to obtain the (R) -3-quinuclidinol chloroformate (C).
3. The process for synthesizing solifenacin succinate as claimed in claim 1, wherein: and in the second step, (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline (A) and an acid-binding agent are added into a reaction solvent, a chloroformic acid- (R) -3-quinuclidine ester (C) solution which is dissolved and diluted by the reaction solvent is dropwise added in an ice bath, stirring is carried out for 3-10 min after the addition is finished, an ice water bath is removed, stirring reaction is continued, a crude product of the solifenacin (D) is obtained by concentration, the crude product of the solifenacin (D) is dissolved by a post-treatment solvent, an organic phase is washed, and the solifenacin (D) is obtained by concentration.
4. The process for synthesizing solifenacin succinate as claimed in claim 1, wherein: the preparation method of solifenacin succinate in the third step comprises the specific steps of adding solifenacin (D) into ethyl acetate, adding absolute ethyl alcohol and succinic acid, heating to reflux, naturally cooling for crystallization after reflux reaction, filtering and drying to obtain the solifenacin succinate.
5. The process for synthesizing solifenacin succinate as claimed in claim 2, wherein: the reaction substance in the first step is one of phosgene, diphosgene and triphosgene; the reactant of the present invention is preferably diphosgene.
6. The process for synthesizing solifenacin succinate as claimed in claim 2, wherein: in the first step, the solvent is one of acetonitrile, tetrahydrofuran and dioxane; acetonitrile is preferred as the solvent of the present invention.
7. The process for synthesizing solifenacin succinate as claimed in claim 3, wherein: in the second step, the acid-binding agent is one of morpholine, N-methylmorpholine, triethylamine, pyridine or 4-methylpyridine; triethylamine is preferred as the acid-binding agent of the invention.
8. The process for synthesizing solifenacin succinate as claimed in claim 3, wherein: in the second step, the reaction solvent is one of tetrahydrofuran, dichloromethane and dioxane; the solvent for the reaction of the present invention is preferably dichloromethane.
9. The process for synthesizing solifenacin succinate as claimed in claim 3, wherein: the post-treatment solvent in the second step is one of ethyl acetate, dichloromethane and methyl tert-butyl ether; the working-up solvent according to the invention is preferably dichloromethane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110393406.0A CN113200979A (en) | 2021-04-13 | 2021-04-13 | Synthesis process of solifenacin succinate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110393406.0A CN113200979A (en) | 2021-04-13 | 2021-04-13 | Synthesis process of solifenacin succinate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113200979A true CN113200979A (en) | 2021-08-03 |
Family
ID=77026709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110393406.0A Pending CN113200979A (en) | 2021-04-13 | 2021-04-13 | Synthesis process of solifenacin succinate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113200979A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017927A (en) * | 1994-12-28 | 2000-01-25 | Yamanouchi Pharmaceutical Co., Ltd. | Quinuclidine derivatives and medicinal composition thereof |
| US20110319621A1 (en) * | 2009-03-09 | 2011-12-29 | Megafine Pharma(P) Ltd. | Method for the preparation of solifenacin and intermediate thereof |
| CN104837828A (en) * | 2012-12-05 | 2015-08-12 | 奇斯药制品公司 | Phenylethylpyridine derivatives as PDE4-inhibitors |
-
2021
- 2021-04-13 CN CN202110393406.0A patent/CN113200979A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017927A (en) * | 1994-12-28 | 2000-01-25 | Yamanouchi Pharmaceutical Co., Ltd. | Quinuclidine derivatives and medicinal composition thereof |
| US20110319621A1 (en) * | 2009-03-09 | 2011-12-29 | Megafine Pharma(P) Ltd. | Method for the preparation of solifenacin and intermediate thereof |
| CN104837828A (en) * | 2012-12-05 | 2015-08-12 | 奇斯药制品公司 | Phenylethylpyridine derivatives as PDE4-inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3398952B1 (en) | Synthesis process of ruxolitinib | |
| CN109705011B (en) | Synthetic method of Upacatinib intermediate and intermediate | |
| JP2008239495A (en) | Method for producing optically active epoxy compound, complex to be used in the method and method for producing the same | |
| CN107337676A (en) | A kind of support method replaces the preparation method of cloth initiation material | |
| CN111315742B (en) | Process for preparing aminopyrimidine derivatives | |
| JP5108383B2 (en) | Process for producing optically active monosulfonate compound | |
| CN104557583B (en) | A kind of method synthesizing γ-aminobutyric acid class chipal compounds | |
| CN113200979A (en) | Synthesis process of solifenacin succinate | |
| CN112430208A (en) | Preparation method of PF-06651600 intermediate | |
| CN110684028B (en) | Preparation method of 2, 6-diazabicyclo [3,3,0] octane compound | |
| CN103896938B (en) | A kind of preparation method of succsinic acid YM-905 | |
| CN112778189A (en) | (3R,4S) -N-substituent-3-carboxylic acid-4-ethyl pyrrolidine, intermediate and lapatinib | |
| CN106554301A (en) | A kind of preparation method of BMS-477118 key intermediate | |
| CN101298448A (en) | Synthetic method of 2-benzyloxy-3-ethyl-4-methyl-5-chloro-6-[(tetrahydro-2H-pyrrole-2-oxyl)methyl ] phenol | |
| CN107089912B (en) | Method for selectively catalyzing and synthesizing mandelate compound by metallocene complex | |
| CA2708141A1 (en) | Intermediates and methods for making zearalenone macrolide analogs | |
| CN106660981A (en) | Process for preparing 2, 3-disubstituted-5-oxopyran compound | |
| CN101044130B (en) | Process for the preparation of glycidyl derivatives | |
| CN107325049B (en) | Preparation method of neratinib intermediate | |
| CN111777554A (en) | Method for synthesizing cisatracurium besilate | |
| CN111072543B (en) | Preparation method and application of (3R,4S) -4-ethylpyrrolidine-3-carboxylic acid compound | |
| US7531662B2 (en) | Cinchona-alkaloid-based catalysts, and asymmetric alcoholysis of cyclic anhydrides using them | |
| CN112939892B (en) | Preparation method of quetiapine | |
| CN110922402B (en) | C-3 iodo-indolizine compound and preparation method thereof | |
| WO2022194022A1 (en) | Method for preparing nalbuphine sebacate and intermediate thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210803 |
|
| WD01 | Invention patent application deemed withdrawn after publication |